CurrentCignaPolicy N/A

Rituxan Hycela (rituximab; hyaluronidase) patient information / prior authorization

Form and policy governing prior authorization and patient information collection for Rituxan Hycela (subcutaneous rituximab + hyaluronidase) requests for Cigna members; intended for prescribing providers, infusion facilities, and pharmacies submitting coverage requests.

Policy Summary

PayerCigna

PolicyRituxan Hycela prior authorization / patient information

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionComplete and submit the prior authorization form with medication details and attach supportive documentation (chart notes, labs/tests).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5response time (business days)

2vial options

>15listed diagnoses

Accredopreferred specialty pharmacy

Coverage Criteria and Indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Supportive documentation (chart notes, lab/test results, etc.) must be attached for all answers

Required for all requests

Prior IV rituximab: Indicate whether patient has already received at least one prior IV dose of rituximab

Field on form to document prior IV rituximab exposure

Regimen- and diagnosis-specific questions: Form asks conditionally about combination regimens, prior chemotherapy, maintenance use, relapsed/refractory status, single-agent use, and retreatment depending on diagnosis (examples: for CLL—use with fludarabine + cyclophosphamide; for DLBCL—prior chemotherapy and use with CHOP/anthracycline or single-agent for previously treated disease; for FL—first-line combination vs maintenance vs relapsed/refractory and response to prior rituximab-containing therapy)

Multiple conditional questions captured on form (see respective diagnosis sections)

Biosimilar alternatives for new starts: For new starts, requester must indicate whether the patient has tried Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), AND Truxima (rituximab-abbs); if not tolerating, indicate whether intolerance is due to inactive-ingredient-related allergy or serious adverse reaction

Impacts consideration of Rituxan Hycela when biosimilar alternatives are available

Per the prior authorization form, infusion of Rituxan Hycela MUST occur in the lowest cost, medically appropriate setting for some Cigna plans. The form asks whether the infusion is being provided in a hospital outpatient–affiliated facility and whether the patient is a candidate for redirection to an alternate, lower-cost setting (for example, ambulatory infusion suite, stand-alone infusion center, or home) with assistance from a Specialty Care Option Case Manager. If redirection is not appropriate, the requester should provide a clear medical necessity rationale explaining why the higher-cost setting is required.

The form explicitly requires that supportive documentation (chart notes, lab/test results, etc.) for all answers must be attached at the time of submission. Requests submitted without the required documentation or without completed clinical responses on the form may be considered incomplete and are at risk for non-processing or denial.

Coding and Dose Information

Requested J-codemixed

J-code

Field on form for applicable J-code to be provided by requester

Dose vial options

Vial option 1Rituxan Hycela 1400mg — 23,400 units vial

Vial option 2Rituxan Hycela 1600mg — 26,800 units vial

Dose/administration fields on formForm includes fields for dose and quantity, frequency of administration, duration of therapy, and J-code

Provider Actions, Documentation, and Prior Authorization

Prior Authorization

Prior Authorization Required and Response Time

Prior authorization form must be completed and submitted with medication details (drug name, strength, dose, quantity, duration, J‑code, frequency, ICD‑10, indication, and whether this is new start or continuation). Save time by submitting online at www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR. Our standard response time for prescription drug coverage requests is 5 business days; if urgent, call to expedite.

Include: medication name, strength, dose, quantity, duration, J‑code, frequency, ICD‑10, indication, prior IV rituximab dose status, and whether new start or continuation.
Online submission: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in EHR.
Standard response time: 5 business days; call if urgent to expedite.

Documentation Required

Supportive Documentation Required

This drug requires supportive documentation for all answers on the prior authorization form. Attach relevant chart notes, lab results, pathology reports, imaging, and any other test results that substantiate the diagnosis and treatment plan. Requests submitted without required supporting documentation may be delayed, not processed, or denied.

Supportive documentation must be attached to the request (chart notes, labs, test results, pathology/imaging).
Missing documentation = possible delay, non‑processing, or denial.

Denial Risk

Requests Lacking Required Documentation May Be Denied or Not Processed

If the request lacks required supportive documentation, it may be denied or not processed. Providers will be notified and may be given the opportunity to submit missing information; however, failure to provide complete documentation at time of submission can lead to denial.

Requests missing required documentation may be denied or not processed.
Providers may be contacted to provide missing information, but timely submission is the responsibility of the provider.

Documentation Required

Biosimilar Alternatives Documentation

For new starts, documentation must indicate whether the patient has tried ALL specified rituximab biosimilars (Riabni [rituximab‑arrx], Ruxience [rituximab‑pvvr], and Truxima [rituximab‑abbs]) prior to Rituxan Hycela. If the patient cannot use the alternatives due to a formulation difference in inactive ingredients causing a significant allergy or serious adverse reaction, this must be documented.

Document trial of Riabni (rituximab‑arrx), Ruxience (rituximab‑pvvr), and Truxima (rituximab‑abbs) for new starts, unless contraindicated.
If unable to use biosimilars due to inactive‑ingredient allergy or serious adverse reaction, include prescriber rationale and supporting documentation.

Background

Rituxan Hycela is the subcutaneous formulation of rituximab combined with hyaluronidase intended for use across multiple B‑cell malignancies and related disorders. The prior authorization form captures the intended diagnosis, planned combination regimens (for example, fludarabine plus cyclophosphamide for CLL or CHOP/anthracycline‑based regimens for DLBCL), whether therapy is first‑line, maintenance, or for relapsed/refractory disease, and details about single‑agent versus combination use to inform medical necessity determination. Because this product is administered subcutaneously, the form emphasizes documentation of clinical intent and prior therapy to support coverage decisions.

Definitions

New start vs continuation

Form distinguishes start vs continuationForm asks 'Is this a new start or continuation of therapy?' with options for New start or continuation

Prior doses for continuationIf continuation, form asks 'How many doses of Rituxan Hycela has your patient received to date?'

Prior IV rituximabForm asks whether the patient has already received at least one intravenous (IV) dose of rituximab (Yes/No)

Line of Therapy Criteria

First-line

Covered when information on intended first-line use is provided.

First-line use: Form indicates Rituxan Hycela is being used in combination with first-line chemotherapy or as first-line therapy for the listed diagnosis (where applicable)

Used to determine line of therapy; form captures first-line combination vs other intents

Regimens and Combination Use

Indication	Regimen question	Coverage status
Chronic lymphocytic leukemia (CLL)
Is Rituxan Hycela going to be used in combination with fludarabine and cyclophosphamide? (Yes/No)
Covered with criteria

Indication	Regimen question(s)	Coverage status
Diffuse large B-cell lymphoma (DLBCL)
Has patient received any other chemotherapy before for this diagnosis?; Is Rituxan Hycela going to be used in combination with CHOP or anthracycline-based chemotherapy?; If previously treated: will Rituxan Hycela be used as single-agent therapy? If single-agent and previously treated: is disease relapsed or refractory?
Covered with criteria

Indication	Regimen/usage options captured on form	Coverage status
Follicular lymphoma (FL)
Form captures use with first-line chemotherapy; as maintenance therapy; or for treatment of relapsed or refractory disease. For maintenance: asks if patient had partial or complete response to first-line rituximab-containing chemotherapy; asks if maintenance will be single-agent. For post-CVP use: asks if being used after CVP and if disease is stable. For relapsed/refractory: asks if used as retreatment and if single-agent.
Covered with criteria

Indication	Regimen question	Coverage status
Relapsed or refractory disease (non-single-agent; age 18+)
Will Rituxan Hycela be used in combination with lenalidomide and tafasitamab-cxix? (Yes/No)
Covered with criteria